463 related articles for article (PubMed ID: 27842666)
21. Diagnostic value of whole-body ultra-low dose computed tomography in comparison with spinal magnetic resonance imaging in the assessment of disease in multiple myeloma.
Ippolito D; Talei Franzesi C; Spiga S; Besostri V; Pezzati S; Rossini F; Sironi S
Br J Haematol; 2017 May; 177(3):395-403. PubMed ID: 28233900
[TBL] [Abstract][Full Text] [Related]
22. [Current approaches in multiple myeloma and other cancer-related bone diseases].
Engelhardt M; Kleber M; Udi J; Wäsch R
Dtsch Med Wochenschr; 2012 May; 137(20):1057-61. PubMed ID: 22549292
[TBL] [Abstract][Full Text] [Related]
23. Value of FDG PET in the assessment of patients with multiple myeloma.
Bredella MA; Steinbach L; Caputo G; Segall G; Hawkins R
AJR Am J Roentgenol; 2005 Apr; 184(4):1199-204. PubMed ID: 15788594
[TBL] [Abstract][Full Text] [Related]
24. Implemented myeloma management with whole-body low-dose CT scan: a real life experience.
Mangiacavalli S; Pezzatti S; Rossini F; Doni E; Cocito F; Bolis S; Corso A
Leuk Lymphoma; 2016 Jul; 57(7):1539-45. PubMed ID: 26788613
[TBL] [Abstract][Full Text] [Related]
25. Whole-body low-dose multidetector row-CT in the diagnosis of multiple myeloma: an alternative to conventional radiography.
Horger M; Claussen CD; Bross-Bach U; Vonthein R; Trabold T; Heuschmid M; Pfannenberg C
Eur J Radiol; 2005 May; 54(2):289-97. PubMed ID: 15837412
[TBL] [Abstract][Full Text] [Related]
26. Value of whole body MRI and dynamic contrast enhanced MRI in the diagnosis, follow-up and evaluation of disease activity and extent in multiple myeloma.
Dutoit JC; Vanderkerken MA; Verstraete KL
Eur J Radiol; 2013 Sep; 82(9):1444-52. PubMed ID: 23726124
[TBL] [Abstract][Full Text] [Related]
27. Dual-Energy CT-Based Bone Marrow Imaging in Multiple Myeloma: Assessment of Focal Lesions in Relation to Disease Status and MRI Findings.
Werner S; Krauss B; Horger M
Acad Radiol; 2022 Feb; 29(2):245-254. PubMed ID: 33707044
[TBL] [Abstract][Full Text] [Related]
28. Multiple Myeloma: Molecular Imaging with 11C-Methionine PET/CT--Initial Experience.
Dankerl A; Liebisch P; Glatting G; Friesen C; Blumstein NM; Kocot D; Wendl C; Bunjes D; Reske SN
Radiology; 2007 Feb; 242(2):498-508. PubMed ID: 17179397
[TBL] [Abstract][Full Text] [Related]
29. A novel combination of bortezomib, lenalidomide, and clarithromycin produced stringent complete response in refractory multiple myeloma complicated with diabetes mellitus - clinical significance and possible mechanisms: a case report.
Takemori N; Imai G; Hoshino K; Ooi A; Kojima M
J Med Case Rep; 2018 Feb; 12(1):40. PubMed ID: 29454372
[TBL] [Abstract][Full Text] [Related]
30. Accuracy of whole-body low-dose multidetector CT (WBLDCT) versus skeletal survey in the detection of myelomatous lesions, and correlation of disease distribution with whole-body MRI (WBMRI).
Gleeson TG; Moriarty J; Shortt CP; Gleeson JP; Fitzpatrick P; Byrne B; McHugh J; O'Connell M; O'Gorman P; Eustace SJ
Skeletal Radiol; 2009 Mar; 38(3):225-36. PubMed ID: 19009290
[TBL] [Abstract][Full Text] [Related]
31. Inter-observer agreement for the evaluation of bone involvement on Whole Body Low Dose Computed Tomography (WBLDCT) in Multiple Myeloma (MM).
Zacchino M; Bonaffini PA; Corso A; Minetti V; Nasatti A; Tinelli C; Dore R; Calliada F; Sironi S
Eur Radiol; 2015 Nov; 25(11):3382-9. PubMed ID: 25987427
[TBL] [Abstract][Full Text] [Related]
32. Sensitivity of whole-body CT and MRI versus projection radiography in the detection of osteolyses in patients with monoclonal plasma cell disease.
Wolf MB; Murray F; Kilk K; Hillengass J; Delorme S; Heiss C; Neben K; Goldschmidt H; Kauczor HU; Weber MA
Eur J Radiol; 2014 Jul; 83(7):1222-1230. PubMed ID: 24793843
[TBL] [Abstract][Full Text] [Related]
33. Whole-Body Imaging of Multiple Myeloma: Diagnostic Criteria.
Ormond Filho AG; Carneiro BC; Pastore D; Silva IP; Yamashita SR; Consolo FD; Hungria VTM; Sandes AF; Rizzatti EG; Nico MAC
Radiographics; 2019; 39(4):1077-1097. PubMed ID: 31283452
[TBL] [Abstract][Full Text] [Related]
34. Whole-body MRI quantitative biomarkers are associated significantly with treatment response in patients with newly diagnosed symptomatic multiple myeloma following bortezomib induction.
Latifoltojar A; Hall-Craggs M; Bainbridge A; Rabin N; Popat R; Rismani A; D'Sa S; Dikaios N; Sokolska M; Antonelli M; Ourselin S; Yong K; Taylor SA; Halligan S; Punwani S
Eur Radiol; 2017 Dec; 27(12):5325-5336. PubMed ID: 28656463
[TBL] [Abstract][Full Text] [Related]
35. Mid-term response assessment in multiple myeloma using a texture analysis approach on dual energy-CT-derived bone marrow images - A proof of principle study.
Reinert CP; Krieg EM; Bösmüller H; Horger M
Eur J Radiol; 2020 Oct; 131():109214. PubMed ID: 32835853
[TBL] [Abstract][Full Text] [Related]
36. Whole-body low-dose computed tomography (WBLDCT) in staging and re-staging of multiple myeloma.
Ippolito D; Giandola T; Maino C; Pecorelli A; Ragusi M; Porta M; Gandola D; Franzesi CT; Sironi S
Ann Hematol; 2021 May; 100(5):1241-1249. PubMed ID: 33660034
[TBL] [Abstract][Full Text] [Related]
37. Association of osteolytic lesions, bone mineral loss and trabecular sclerosis with prevalent vertebral fractures in patients with multiple myeloma.
Borggrefe J; Giravent S; Campbell G; Thomsen F; Chang D; Franke M; Günther A; Heller M; Wulff A
Eur J Radiol; 2015 Nov; 84(11):2269-74. PubMed ID: 26283192
[TBL] [Abstract][Full Text] [Related]
38. Treatment response evaluation with
Sachpekidis C; Hillengass J; Goldschmidt H; Wagner B; Haberkorn U; Kopka K; Dimitrakopoulou-Strauss A
Eur J Nucl Med Mol Imaging; 2017 Jan; 44(1):50-62. PubMed ID: 27573638
[TBL] [Abstract][Full Text] [Related]
39. Imaging of Multiple Myeloma.
Kosmala A; Bley T; Petritsch B
Rofo; 2019 Sep; 191(9):805-816. PubMed ID: 31185511
[TBL] [Abstract][Full Text] [Related]
40. Multiple myeloma: is a shift toward continuous therapy needed to move forward?
Guglielmelli T; Palumbo A
Expert Rev Hematol; 2015 Jun; 8(3):253-6. PubMed ID: 25582032
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
